Selective internal radiation therapy (SIRT) fails to extend survival in the SORAMIC study palliative cohort

(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: Available online 15 October 2019Source: Life SciencesAuthor(s): La Hu, Zicheng Zeng, Qing Xia, Zhaoyu Liu, Xiao Feng, Jitao Chen, Mengqiu Huang, Liangcai Chen, Zhiyuan Fang, Qiuzhen Liu, Hongbo Zeng, Xinke Zhou, Jifang LiuAbstractAimsEnhanced aerobic glycolysis is an essential hallmark of malignant cancer. Blocking the glycolytic pathway has been suggested as a therapeutic strategy to impair the proliferation of tumor cells. Metformin, a widely used anti-diabetes drug, exhibits anti-tumor properties. However, the underlying molecular mechanism of its action linking glucose metabolism with the suppression ...
Source: Life Sciences - Category: Biology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
概 要目 的研究肝癌细胞缺氧微环境导致 miR-210 表达变化与肿瘤进展、 预后等相关性。创新点首次阐明了 miR-210 表达与肝癌预后及缺氧相关基因的关系。方 法选取肿瘤基因数据库 (TCGA) 中 424 位肝癌患者的 miR-210 表达水平、 临床病理参数及缺氧相关基因 (HIF1 α、HIF3 α、PTPN1和BNIP3) 表达量, 研究 miR-210 与肝癌预后及缺氧基因之间的相关性。结 论miR-210 的表达与肝细胞癌进展分期呈正相关, 它的高表达预示更低的无瘤生存率。 因此, 推测 miR-210 可能与肿瘤细胞缺氧相关性死亡有关。
Source: Journal of Zhejiang University. Science. B. - Category: Universities & Medical Training Source Type: research
The immune environment in primary tumor has a profound impact on immunotherapy. However, the clinical relevance of immune environment in hepatocellular carcinoma (HCC) is largely unknown. Here, the immune profile and its clinical response in HCC were investigated. The gene expression profiles of 569 HCCs from three cohorts (The Cancer Genome Atlas, TCGA, n = 257; Gene Expression Omnibus, GEO, n = 170; International Cancer Genome Consortium, ICGC, n = 142) were used in the current study. Five gene expression subtypes (C1–C5) responsible for global immune genes were identified in HCCs at stage I/II. It was found that s...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Targeted delivery of therapeutic compounds to particular cell types such that they only affect the target cells is of great clinical importance since it can minimize undesired side effects. For example, typical chemotherapeutic treatments used in the treatment of neoplastic disorders are cytotoxic not only to cancer cells but also to most normal cells when exposed to a critical concentration of the compound. As such, many chemotherapeutics exhibit severe side effects, often prohibiting their effective use in the treatment of cancer. Here, we describe a new means for facilitated delivery of a clinically used chemotherapy co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions: LysoPC (24:0) could distinguished HCC from HBG, and 8 SCMs distinguished HCC from healthy controls. LysoPC and other metabolites have the potential to serve as non-invasive biomarkers for HBV related AFP– and AFP+ HCC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewHepatocellular carcinoma (HCC) surveillance in patients with cirrhosis is associated with decreased mortality by enabling early tumor detection. However, the benefits of any cancer screening program must be considered in light of potential physical, financial, and psychological harms, as well as the risk of overdiagnosis. Herein, we summarize the potential harms of HCC surveillance.Recent FindingsTo date, two retrospective studies have addressed physical harms of HCC surveillance. Based on these data, 15% to 28% of patients undergoing HCC surveillance experience physical harm including additional c...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
ConclusionOur study demonstrated a significant correlation between Nectin-4 expression and tumor grade as well as stages (p 
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
caens Immunotherapies targeting immune checkpoints are fast-developing therapeutic approaches adopted for several tumor types that trigger unprecedented rates of durable clinical responses. Immune checkpoint programmed cell death protein 1 (PD-1), expressed primarily by T cells, and programmed cell death ligand 1 (PD-L1), expressed mainly by tumor cells, macrophages, and dendritic cells, are molecules that impede immune function, thereby allowing tumor cells to proliferate, grow and spread. PD-1/PD-L1 checkpoint inhibitors have emerged as a promising treatment strategy of hepatocellular carcinoma (HCC). However, only a...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
We report that PL may interact with thioredoxin reductase 1 (TrxR1), an important selenocysteine (Sec)-containing antioxidant enzyme, and induce reactive oxygen species (ROS)-mediated apoptosis in HCC cells. Our results suggest that PL induces a lethal endoplasmic reticulum (ER) stress response in HCC cells by targeting TrxR1 and increasing intracellular ROS levels. Notably, PL treatment reduces TrxR1 activity and tumor cell burden in vivo. Additionally, TrxR1 is significantly upregulated in existing HCC databases and available HCC clinical specimens. Taken together, these results suggest PL as a novel anticancer candidate...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Palliative | Radiation Therapy | Study | Urology & Nephrology